Kymera Therapeutics Hits New 52-Week High of $56.81, Up 64% Year-to-Date

Kymera Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 56.81 on September 26, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, particularly notable given its market capitalization of USD 3,093 million, categorizing it as a small-cap stock.
Over the past year, Kymera Therapeutics has demonstrated impressive growth, with a performance increase of 64.19%, significantly outpacing the S&P 500's 15.64% gain during the same period. Despite being a loss-making entity, the company continues to attract attention within its industry.

Key financial metrics reveal a price-to-book ratio of 3.18, indicating how the market values the company's equity relative to its book value. Additionally, the company's debt-to-equity ratio stands at -0.67, reflecting a unique financial structure. However, it is important to note that the company does not offer a dividend yield, and its return on equity is currently at -28.35%.

Kymera Therapeutics' recent performance highlights its position in the market and the potential for continued interest in its developments.